© 2017 Ixchel Pharma
Ixchel seeks licensees and partners with interest in orphan mitochondrial disease. We are familiar with the clinical trial designs adaptable to orphan mitochondrial disease, thus expediting future development efforts.
Bringing mitochondrial research to life
We are devoted to developing drugs that treat the mechanistic causes of orphan mitochondrial diseases.
Ixchel Pharma develops small-molecule drugs that ameliorate mitochondrial disease. Our patented prodrug technology delivers bioactive fumarate molecules with superior pharmacokinetics to other prodrugs. The superior PK of our molecules causes greater pharmacodynamic potency to ameliorate mouse models of mitochondrial diseases including Friedreich's ataxia and Leigh Syndrome.
Ixchel focuses on developing drugs that cure mitochondrial diseases for which there are currently no FDA-approved treatments. The majority of mitochondrial diseases are considered orphan and affect less than 200,000 people in the US.